Dexmedetomidine in Neurocritical Care

Mohammadreza Hajiesmaeili; Leila Simani; razieh hajisoltani; Reza Goharani; Marjan Asadollahi; Mahdi Amirdosara; Majid Mokhtari

doi:10.22037/jcma.v5i4.30725

Journal of Cellular & Molecular Anesthesia

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement New Publisher Announcement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

https://doi.org/10.22037/jcma.v5i4.30725

Dexmedetomidine in Neurocritical Care

Author(s):

Mohammadreza Hajiesmaeili

^,*,

Leila Simani

,

razieh hajisoltani,

Reza Goharani,

Marjan Asadollahi

,

Mahdi Amirdosara,

Majid Mokhtari

Journal of Cellular & Molecular Anesthesia:Vol. 5, issue 4; e149628

Published online:Jun 14, 2020

Article type:Review

How to Cite:Mohammadreza HajiesmaeiliLeila Simanirazieh hajisoltaniReza GoharaniMarjan AsadollahiMahdi AmirdosaraMajid Mokhtariet al.Dexmedetomidine in Neurocritical Care.J Cell Mol Anesth.5(4):e149628.https://doi.org/10.22037/jcma.v5i4.30725.

Abstract

Early and appropriate management of brain insults has significantly reduced patient morbidity and mortality. Neuromonitoring, neuroprotection and secondary brain injury prevention are the essential principals of brain injury management. In this literature review we have elaborated the neuroprotective role of dexmedetomidine (DEX), predominantly in different animal models of brain insults and reports in patients cared in a neurocritical care setting. ?We undertook an electronic literature search of articles published in English prior to July 2019. This search resulted in inclusion of 59 studies from medical databanks such as PubMed, Scopus, EMBSCO, CINAHL, ISC and the Cochrane Library. The keywords used were brain, ?2 agonist, neurocritical care and dexmedetomidine. DEX may have a neuroprotective effect in a broad spectrum of brain pathologies such as traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), ischemic stroke, intracerebral hemorrhage (ICH), and cerebral hypoxia. However, its neuroprotective role in status epilepticus (SE) is less clear. Further animal and human studies are needed before we could consider DEX as a neuroprotective agent in this patient population. Due to its favorable properties outlined in this review, DEX could be considered a favorable sedative agent in the neurocritical care settings.

Keywords

dexmedetomidine

Neurocritical care

Neuroprotection

References

1.
References are in the PDF file of the article.

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

CrossRef 0

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Mohammadreza Hajiesmaeili:[PubMed][Scholar]
Leila Simani:[PubMed][Scholar]
razieh hajisoltani:[PubMed][Scholar]
Reza Goharani:[PubMed][Scholar]
Marjan Asadollahi:[PubMed][Scholar]
Mahdi Amirdosara:[PubMed][Scholar]
Majid Mokhtari:[PubMed][Scholar]